Share on StockTwits

Illumina (NASDAQ:ILMN) has been given a consensus recommendation of “Buy” by the twenty ratings firms that are presently covering the stock, AmericanBankingNews.com reports. Five investment analysts have rated the stock with a hold recommendation, ten have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $170.15.

Several analysts have recently commented on the stock. Analysts at Goldman Sachs raised their price target on shares of Illumina from $184.00 to $187.00 in a research note on Tuesday, August 5th. Separately, analysts at Tigress Financial initiated coverage on shares of Illumina in a research note on Friday, August 1st. They set a “buy” rating on the stock. Finally, analysts at Credit Suisse reiterated an “outperform” rating on shares of Illumina in a research note on Thursday, July 24th. They now have a $198.00 price target on the stock, up previously from $180.00.

Illumina (NASDAQ:ILMN) opened at 167.45 on Wednesday. Illumina has a 1-year low of $72.77 and a 1-year high of $185.00. The stock’s 50-day moving average is $171.2 and its 200-day moving average is $158.9. The company has a market cap of $23.342 billion and a price-to-earnings ratio of 106.33.

Illumina (NASDAQ:ILMN) last announced its earnings results on Wednesday, July 23rd. The company reported $0.57 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.50 by $0.07. The company had revenue of $448.00 million for the quarter, compared to the consensus estimate of $426.50 million. During the same quarter in the prior year, the company posted $0.43 earnings per share. The company’s quarterly revenue was up 29.5% on a year-over-year basis. On average, analysts predict that Illumina will post $2.29 earnings per share for the current fiscal year.

In other Illumina news, Director A Blaine Bowman sold 5,000 shares of Illumina stock in a transaction dated Tuesday, August 5th. The stock was sold at an average price of $159.91, for a total transaction of $799,550.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Illumina, Inc (NASDAQ:ILMN) is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function.

Receive News & Ratings for Illumina Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.